Shares of Anavex Life Sciences climbed 7.25% to €2.21 on Wednesday, recovering from a recent 52-week low of €1.97 hit on July 14, as the biotech company moved to address its Nasdaq listing concerns while simultaneously unveiling fresh scientific support for its lead drug candidate, Blarcamesine. The stock remains deep in the red year-to-date, however, with losses of 29.82% still on the books.
The rally came after Anavex submitted a formal compliance plan to the Nasdaq on July 20, responding to a deficiency notice the exchange issued on May 20 over the delayed filing of its quarterly Form 10-Q. Under Nasdaq Listing Rule 5250(c)(1), the company had to present a plan to regain compliance with reporting requirements. The exchange is now reviewing the submission, and the stock continues to trade under the ticker AVXL during the process. If the plan is rejected, Anavex could face a hearing to stave off a potential delisting from the Nasdaq Global Select Market.
Parallel to the regulatory filing, Anavex announced the publication of a study in the Proceedings of the National Academy of Sciences (PNAS) that bolsters the scientific rationale behind Blarcamesine. The research identifies dysfunction in autophagy—the cellular mechanism that clears damaged components—as an early driver in Alzheimer’s disease. Blarcamesine, a SIGMAR1 activator, is designed to restore this process in neurons. “Targeting these upstream defects is essential to achieve disease-modifying benefits for patients,” said CEO Christopher Missling, contrasting the approach with competitors focused on amyloid plaque removal.
Should investors sell immediately? Or is it worth buying Anavex?
The PNAS publication adds weight to Anavex’s hypothesis at a time when the broader Alzheimer’s research field is gaining momentum. The World Health Organization recently highlighted that nearly half of all dementia cases are linked to modifiable risk factors, while separate work from the University of Kentucky has pinpointed microglial overactivation as a contributor to sleep disturbances in dementia patients. Meanwhile, at the AAIC conference in London, rival firms such as Biogen and Alnylam presented updates on their own programs, underscoring the competitive landscape that Anavex must navigate.
Analysts remain optimistic about the stock’s prospects despite the recent turbulence. A buy rating stands with a price target of $20, reflecting confidence in the clinical pipeline rather than near-term accounting hiccups. The compliance plan now pending with Nasdaq will be a key near-term catalyst; acceptance would allow Anavex to catch up on its financial filings and remove the overhang of a possible delisting. Longer-term, the company’s ability to translate the autophagy hypothesis into positive clinical results will determine whether the stock can regain its footing after a punishing first half of the year.
Ad
Anavex Stock: Buy or Sell?! New Anavex Analysis from July 20 delivers the answer:
The latest Anavex figures speak for themselves: Urgent action needed for Anavex investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 20.
Anavex: Buy or sell? Read more here...
